Figure 5
Changes in mouse activity can accurately detect the effects of prophylactic and therapeutic treatment of Copaxone in mice induced with EAE. (A) Average clinical EAE score of HLA-DR3.DQ8 Tg mice immunized on day 0 with PLP91–110 with CFA/PTX and treated with Copaxone or PBS on day −10. Mice were assessed daily using standard disease scoring for 20 days post-immunization. (B) Cumulative EAE score of HLA-DR3.DQ8 Tg mice in A. (C) Average spontaneous vertical activity of HLA-DR3.DQ8 Tg EAE mice in A. Measurements of daily average nocturnal activity were obtained up to day 19. (D) Average clinical EAE score (right Y-axis) and spontaneous vertical activity (inverted left Y-axis) of mice in A that were only treated with PBS. (E) Average clinical EAE score (right Y-Axis) and spontaneous vertical activity (inverted left Y-axis) of mice in A that were only treated with Copaxone. (F) Average clinical EAE score of HLA-DR3.DQ8 Tg mice immunized on day 0 with PLP91–110 with CFA/PTX and treated with Copaxone or PBS on day 10. Mice were assessed daily using standard EAE disease scoring for 20 days post-immunization. (G) Average spontaneous vertical activity of HLA-DR3.DQ8 Tg EAE mice treated with Copaxone or PBS as in F. Measurements of daily average nocturnal activity were obtained up to day 19. For plots (A–E), the data presented represent one of three experiments performed (n ≥ 7 mice per group). p-values determined by multiple t tests using the Holm-Sidak method (A) and the Mann- Whitney unpaired t test (C). * indicates p ≤ 0.05, when compared to the PBS-challenged group. For plots (F,G), p-values for average clinical EAE score (F) and vertical activity analysis (G) determined by one-way ANOVA with Dunnett’s multiple comparisons test. **** indicates p < 0.0001, when compared to the PBS-challenged group.
